Home › Precursor T-Cell Lymphoblastic Leukemia-Lymphoma › Pennsylvania › Philadelphia
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma clinical trials in Philadelphia, PA
4 studies for Precursor T-Cell Lymphoblastic Leukemia-Lymphoma are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
RecruitingPhase 2
- Children's Hospital of Philadelphia, Philadelphia
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
RecruitingPhase 1
- Children's Hospital of Philadelphia, Philadelphia
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
RecruitingPhase 1
- Children's Hospital of Philadelphia, Philadelphia
A Registry for People With T-cell Lymphoma
RecruitingObservational study
- University of Pennsylvania (Data Collection Only), Philadelphia
- Thomas Jefferson University Hospital (Data collection only), Philadelphia
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma trials in other cities
- Houston, TX8 studies
- New York City, NY6 studies
- Columbus, OH5 studies
- Washington, DC5 studies
- New Rochelle, NY3 studies
- Edison, NJ3 studies
- Staten Island, NY3 studies
- East Norwalk, CT3 studies
- Queens, NY3 studies
- St. Louis, MO3 studies
- Boston, MA3 studies
- Baldwin Park, CA3 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.